Clinical trial · Interventional
Thalidomide-Dexamethasone for Multiple Myeloma
NCT00038090CI-TRIAL-00035537completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Thalidomide | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Thalidomide + Dexamethasone
- interventionNames
- Drug: Thalidomide
- Drug: Dexamethasone
Primary outcomes (1)
- measure
- Response Rate
- timeFrame
- Baseline, with each course and monthly tests
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
* Previously untreated patients with symptomatic or progressive asymptomatic multiple myeloma. Criteria for progression among patients with asymptomatic disease include new lytic bone lesions, rise of serum myeloma protein to \>5.0 gm/dl or fall of Hgb to \<10.5 gm/dl. * Overt infection or unexplained fever should be resolved before treatment or treated concurrently with antibiotics. * Patients must provide written informed consent indicating that they are aware of the investigational nature of this study. * Patients with idiopathic monoclonal gammopathy or stable asymptomatic myeloma are ineligible. * Patients whose only prior therapy has been with local radiotherapy or alpha interferon are eligible. * Patients treated with steroids in order to stabilize disease within 60 days prior to enrollment are eligible. * Patients exposed to longer periods of high-dose glucocorticoid, or with any exposure to thalidomide or alkylating agent are ineligible.
References
Publications (0)
Data not yet available
No reference posted for this study.